SCHEMBL4140219

SCHEMBL4140219

CC(=O)Nc1cc(C(C)(C)C)c(O)c(C(=O)Nc2ccc(C#N)cc2OC(F)(F)F)c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 1/20 0.38
PTGFR P43088 1/20 0.35
PDK1 Q15118 2/20 0.35
PDK2 Q15119 2/20 0.35
PDK3 Q15120 2/20 0.35
PDK4 Q16654 2/20 0.35
XDH P47989 1/20 0.34
SLC22A12 Q96S37 1/20 0.34
ALDH1A1 P00352 2/20 0.34
GAA P10253 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
TMPRSS4 Q9NRS4 1/20 0.33
CNR2 P34972 1/20 0.33
BACE2 Q9Y5Z0 1/20 0.33
CACNA1G O43497 1/20 0.32
CACNA1H O95180 1/20 0.32
CYP3A4 P08684 1/20 0.32
CACNA1C Q13936 1/20 0.32
CACNA1I Q9P0X4 1/20 0.32
HCRTR1 O43613 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4138666 0.89 GCGR (0.39) GCGRPTGFRPDK1PDK2PDK3
SCHEMBL4148816 0.89 GCGR (0.38) GCGRPTGFRPDK1PDK2PDK3
SCHEMBL4150028 0.89 GCGR (0.39) GCGRPTGFRPDK1PDK2PDK3
SCHEMBL4149540 0.89 GCGR (0.39) GCGRPTGFRPDK1PDK2PDK3
SCHEMBL3170148 0.88 PTGFR (0.39) GCGRPTGFRPDK1PDK2PDK3
SCHEMBL4136944 0.88 PDK1 (0.42) GCGRPTGFRPDK1PDK2PDK3
SCHEMBL4146506 0.88 GCGR (0.39) GCGRPTGFRPDK1PDK2PDK3
SCHEMBL4146555 0.88 PGR (0.45) GCGRPTGFRPDK1PDK2PDK3
SCHEMBL4133940 0.87 GCGR (0.36) GCGRPTGFRPDK1PDK2PDK3
SCHEMBL4146334 0.86 CNR2 (0.38) GCGRPTGFRPDK1PDK2PDK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062396-A1 Novel Haloalkoxy-Substituted Salicylic Anilides NOVO NORDISK A/S (DK) 2009-03-05 US claimed
EP-1888508-A2 NOVEL HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES NOVO NORDISK A/S (DK) 2008-02-20 EP claimed
WO-2006125781-A2 HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES NOVO NORDISK A/S (DK) 2006-11-30 WO claimed
US-20240074995-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FIRST WAVE BIO, INC. 2024-03-07 US disclosed
US-10912746-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory response FIRST WAVE BIO, INC. (US) 2021-02-09 US disclosed
US-10849867-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory response FIRST WAVE BIO, INC. (US) 2020-12-01 US disclosed
US-10799468-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory responses FIRST WAVE BIO, INC. (US) 2020-10-13 US disclosed
US-10772854-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory response FIRST WAVE BIO, INC. (US) 2020-09-15 US disclosed
US-20200276140-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FIRST WAVE BIO, INC. 2020-09-03 US disclosed
US-10744103-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory responses FIRST WAVE BIO, INC. (US) 2020-08-18 US disclosed
US-20200197340-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FIRST WAVE BIO, INC. 2020-06-25 US disclosed
US-20200147012-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FIRST WAVE BIO, INC. 2020-05-14 US disclosed
US-20200147013-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FIRST WAVE BIO, INC. 2020-05-14 US disclosed
US-20190298670-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES MONTERESEARCH S.R.L. (IT) 2019-10-03 US disclosed
US-20090062396-A1 Novel Haloalkoxy-Substituted Salicylic Anilides NOVO NORDISK A/S (DK) 2009-03-05 US disclosed
EP-1888508-A2 NOVEL HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES NOVO NORDISK A/S (DK) 2008-02-20 EP disclosed
WO-2006125781-A2 HALOALKOXY-SUBSTITUTED SALICYLIC ANILIDES NOVO NORDISK A/S (DK) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200147012-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FH, CS, ECHS1 GCGR 1865/4885PTGFR 2821/4885PDK1 1128/4885
US-20240074995-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FH, CS, ECHS1 GCGR 1865/4885PTGFR 2821/4885PDK1 1128/4885
US-10744103-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory responses FH, CS, ECHS1 GCGR 1865/4885PTGFR 2821/4885PDK1 1128/4885
US-20190298670-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FH, CS, ECHS1 GCGR 1824/4885PTGFR 2799/4885PDK1 1135/4885
US-10849867-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory response FH, CS, ECHS1 GCGR 1721/4885PTGFR 2687/4885PDK1 1159/4885
US-20090062396-A1 Novel Haloalkoxy-Substituted Salicylic Anilides FABP4, HDHD5, HSPD1 GCGR 1042/4885PTGFR 3254/4885PDK1 1672/4885
US-20200197340-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FH, CS, ECHS1 GCGR 1865/4885PTGFR 2821/4885PDK1 1128/4885
US-10799468-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory responses FH, CS, ECHS1 GCGR 1824/4885PTGFR 2799/4885PDK1 1135/4885
US-10912746-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory response FH, CS, ECHS1 GCGR 1758/4885PTGFR 2711/4885PDK1 1149/4885
US-20200147013-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FH, CS, ECHS1 GCGR 1824/4885PTGFR 2799/4885PDK1 1135/4885
US-20200276140-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FH, CS, ECHS1 GCGR 1824/4885PTGFR 2799/4885PDK1 1135/4885
US-10772854-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory response FH, CS, ECHS1 GCGR 1721/4885PTGFR 2687/4885PDK1 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.